Improving antibody production in cells using advanced technology
Official title: Optimizing Antibody Production in CHO Cells Using Epi-MAX Technology to Increase Heavy and Light Chain Expression
Funded at Codomax INC. · NIH-10921744 · Data updated 2026-11-12
This study is exploring a new way to help cells produce more antibodies, which are important for treating various health conditions, by using a special technique that helps the cells handle stress better.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Codomax INC. NIH-funded |
| Lab location | 1 site (Worcester, United States) |
| Project start | April 15, 2024 |
| Project end | April 14, 2026 |
| Funding year | 2024 |
| Award (this year) | $350,000 |
| NIH project number | 1R41TR005122-01 |
| Project ID | NIH-10921744 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for benefiting from this research include patients requiring antibody-based therapies, such as those with autoimmune diseases, cancers, or infectious diseases.
✕Less likely to help
Patients who do not require antibody therapies or those with conditions unrelated to antibody production may not benefit from this research.
What this research studies
This research focuses on enhancing the production of antibodies by optimizing the use of CHO (Chinese hamster ovary) cells through a novel technology called Epi-MAX. The approach involves adjusting the translation process of proteins in response to cellular stress, which can improve the efficiency of antibody synthesis. By matching the genetic code of the target antibodies with the cell's stress response mechanisms, the researchers aim to significantly increase the yield of these important proteins. This could lead to more effective therapies and treatments derived from antibodies.
Why it matters
Potential benefit: If successful, this research could lead to more efficient production of therapeutic antibodies, improving treatment options for various diseases.
How similar studies have gone: Previous research has shown promise in optimizing protein production using similar stress-response mechanisms, indicating potential for success in this novel application.
Where this research is happening
-
Codomax INC.
Worcester, United States Active
Researchers
- Principal investigator: Byrne, Shane — Codomax INC.
- Study coordinator: Byrne, Shane
Related research
Other NIH-funded projects on the same topics.
-
Improving the production of hard-to-make therapeutic proteins using engineered yeast.
This study is exploring a new way to help yeast cells produce important therapeutic proteins more efficiently, which could lead to better treatments for patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.